Site models that meet patient needs at the site level.
The overriding theme in clinical development is “get medicines to the patients faster”-and to that end, many different ideas are in the mix. One of the most significant is this evolution around the patient. To get approved medicines to patients in a clinical trial, you have to find the right patients. Many of the new solutions evolving to meet this need address patients at the site level.
At the DIA Annual Meeting in June, Christian Burns, vice president of BTC Network and ClinEdge; Sean Stanton, president and CEO at LifeCore Solutions; and Jennifer Byrne, co-founder and CEO of the newly launched Javara (see: https://bit.ly/2PzGRmE) presented “Rebuilding or Building a Research Site in the Year 2020.” During the session, they presented five site models and led the audience through an interactive discussion on how each of these are evolving to meet specific challenges. The models include virtual sites; specialty practice with research extension; dedicated research sites; large multi-physician health systems with research embedded;
and academic sites. The audience discussed the pain points around each model as follows:
Specialty practice pain points
Large multi-physician practices pain points
Dedicated research site pain points
Due to the compelling topic and interest, the session didn’t have time to delve into the virtual or academic space pain points. In the table above, SCORR Marketing, our market research survey partner, and Applied Clinical Trials wanted to focus on up-and-coming organizations that are driving innovation in each of the site models. Because of space constraints, we chose one for each, but, of course, we will continue to feature these innovators in upcoming articles in our pages and online.
- Staff report
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.